HAG
BNTC icon

HighPoint Advisor Group’s Benitec Biopharma BNTC Stock Holding History

HighPoint Advisor Group’s Portfolio BNTC Stock Details BNTC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q2 		– Sell
-5,471
Closed -$462K – 559
2021
Q1 		$462K Buy
+5,471
New +$372K 0.05% 288

Other funds holding BNTC

SCM
Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
PWAC
Private Wealth Advisors (California) Fresno, California $356M AUM 26.22% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return
WA
WealthTrust Axiom Wayne, Pennsylvania $406M AUM 40.44% 1-Year Est. Return

HighPoint Advisor Group's BNTC Position: Q2 2021 in Review

HighPoint Advisor Group sold out of Benitec Biopharma (BNTC) in Q2 2021, closing a stake of 5,471 shares — an estimated $462K sold.

HighPoint Advisor Group first reported a position in BNTC in Q1 2021 and held it in 1 quarter. The position peaked at $462K in Q1 2021. 16 funds tracked by Wall St. Rank hold BNTC as of Q2 2021.

  • HighPoint Advisor Group reported no remaining Benitec Biopharma position as of Q2 2021 after selling out during the quarter.
  • HighPoint Advisor Group sold 5,471 Benitec Biopharma shares in Q2 2021, an estimated $462K.
  • HighPoint Advisor Group first reported a position in Benitec Biopharma in Q1 2021 and held it in 1 quarter.
  • HighPoint Advisor Group's Benitec Biopharma position peaked at $462K in Q1 2021.
  • 16 funds tracked by Wall St. Rank held Benitec Biopharma as of Q2 2021.

Based on HighPoint Advisor Group's 13F filing for Q2 2021, filed 29 Jul 2021.